Answer five short questions to see whether the MEDVi program may be relevant to your situation.
This is not a medical evaluation. No clinical determination is made based on your answers. If you choose to proceed after completing this questionnaire, a licensed physician will independently review your full health history and determine whether treatment is appropriate.
What best describes your primary weight management goal?
This helps us understand what you're looking for so we can show you relevant information about the program.
How long have you been actively working on weight management?
GLP-1 programs are generally intended for people who have made sustained lifestyle efforts.
Which of these have you tried? Select the approach you relied on most.
This gives context on your weight management history.
GLP-1 medications are generally considered after someone has made sustained efforts with diet, exercise, or other structured weight management approaches. Based on your response, this program may not be the best fit for you right now.
That doesn't mean it won't be appropriate in the future. If you'd like to start with foundational lifestyle changes and revisit GLP-1 options down the line, your own primary care physician is the best first step.
If you believe your answer didn't fully capture your history and you've actually tried structured methods in the past, you can go back and update your response.
This questionnaire is a paid advertisement for MEDVi and is not a medical evaluation.
Have you looked into brand-name GLP-1 medications before?
This helps us understand what barriers you've encountered.
Ozempic® is a registered trademark of Novo Nordisk A/S. Mounjaro® is a registered trademark of Eli Lilly and Company. Referenced for informational purposes only — no endorsement or affiliation implied.
If this program seems like a fit, how soon would you want to begin a physician evaluation?
No commitment required — this just helps set expectations.
Questionnaire Complete
Your answers indicate you may have a profile similar to adults who are commonly evaluated for GLP-1 medication programs — someone with a sustained history of weight management effort who has found brand-name options financially out of reach.
No eligibility determination has been made based on this questionnaire. If you choose to proceed, a licensed physician will independently review your full health history and determine whether compounded GLP-1 medication is medically appropriate for your individual situation. Not all applicants will qualify for treatment.
Brand-Name GLP-1
$1,000+/mo
Manufacturer list price; actual cost may be lower with insurance or savings programs.
MEDVi Program
$179/mo*
Physician-supervised. Compounded medication.
*$179/month reflects the lowest available starting price during the initial titration phase of compounded semaglutide. Pricing varies by medication type (semaglutide vs. tirzepatide), dosage level, and treatment phase. Higher dosages and tirzepatide formulations are priced higher. Compounded medications are not FDA-approved.
This questionnaire is a paid advertisement for MEDVi. We may receive compensation if you enroll through this page. This is not independent editorial content.
This questionnaire does not constitute a medical evaluation, diagnosis, or treatment recommendation. No clinical determination has been made based on your answers. A licensed physician will independently evaluate your health profile and determine whether treatment is appropriate. Not all applicants will qualify.
Compounded medications are not FDA-approved and have not been tested for bioequivalence to brand-name products such as Ozempic® or Mounjaro®. Clinical trial results commonly cited in media coverage were conducted using brand-name FDA-approved formulations, not compounded versions. These results may not be directly applicable to compounded formulations.
Individual results vary significantly. No specific weight loss results are promised, implied, or guaranteed. GLP-1 medications are intended to be used in conjunction with lifestyle modifications including improved nutrition and increased physical activity.
"$179/month" reflects the lowest starting price during initial titration of compounded semaglutide. Actual cost varies by medication, dosage, and phase. Brand-name price references are based on published manufacturer list prices as of 2026 and may not reflect prices available through insurance, coupons, or patient assistance programs.
Ozempic® is a registered trademark of Novo Nordisk A/S. Mounjaro® is a registered trademark of Eli Lilly and Company. Referenced for informational purposes only — no endorsement or affiliation implied.